Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation - 1 Aug 2018

Zhou Yi, Othus Megan, Walter Roland B, Estey Elihu H, Wu David, Wood Brent L

Abstract excerpt

Relapse is the major cause of death in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT). Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) before and after HCT is a strong, independent risk factor for relapse. As next-generation sequencing (NGS) is increasingly applied in AML MRD detection, it remains to be determined if NGS can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Flow Cytometry
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Predictive Value of Tests

Share to Recurrence

Share to Transplantation, Homologous

Source

Identifiers

PMID: 29684564
DOI: 10.1016/j.bbmt.2018.04.017

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.PMID 29684564Read ↗

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.Semantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Sequencing Identifies Relapse-Prone AML Patients.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapseSemantic proximity Read ↗

Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationSemantic proximity Read ↗

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

MRD evaluation of AML in clinical practice: are we there yet?Semantic proximity Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.